期刊文献+

中药黄常山中常山酮对伤口愈合和瘢痕形成的作用(英文) 被引量:13

Effects of Halofuginone contained in traditional Chinese herb of antifebrile dichroa root on wound healing and cicatrisation
下载PDF
导出
摘要 目的:研究常山酮特异的抑制Ⅰ型胶原合成作用对大鼠伤口愈合和胶原形成的影响。方法:60只大鼠分为口服常山酮(A组)、局部用常山酮(B组)和对照组(C组)3组,于背部脊柱两侧切除皮肤形成伤口,分别给药,术后3,7,14d测定创面面积,切取伤口肉芽组织或已愈伤口瘢痕皮肤,形态学观察伤口愈合情况,放免法分别测量PCI、PCIII的含量,伤口愈合后局部皮肤抗张力强度。结果:应用常山酮后伤口愈合速度较对照组减慢,伤口中PCI含量显著低于对照组,肉芽组织中微血管量减少,同时伤口愈合后皮肤抗张力强度下降。结论:作为特异的Ⅰ型胶原合成抑制剂,常山酮可以控制伤口愈合和Ⅰ型胶原合成,并为防治瘢痕形成提供理论基础。 AIM: To investigate the effects of wound healing and specific inhibition of halofuginone on type I collagen synthesis.METHODS:Sixty rats were divided into 3 groups:orally taking halofuginone group (group A), locally using halofuginone group (group B) and control group (group C) . The wound was made on the dorsum of the rats and agents applied on it respectively. The residual wound surface area was measured and granulation tissue harvested to take the histological observation and the content of PCⅠ and PCⅢ were detected at 3rd,7th and 14th day postoperatively.The skin strength against tearing was obtained after wound healing.RESULTS:The amount of PCⅠ was increased much lower in group A and B than that in control group while the wound healing speed slowed down and micro vessels in wound granulation tissue was decreased markedly in group A and B, and subsequently, the skin strength against tearing was reduced significantly in group A and B.
出处 《中国临床康复》 CSCD 2003年第23期3196-3197,共2页 Chinese Journal of Clinical Rehabilitation
基金 重庆医科大学附属第一医院启动科研基金~~
关键词 中药 黄常山 常山酮 伤口愈合 瘢痕形成 作用 As a specific type I collagen synthesis inhibitor, halofuginone should be a good regulator on wound healing and a novel ,satisfactory agent for treating and preventing scarring.
  • 相关文献

参考文献9

  • 1Granot l, Halevy O, Hurwltz S. et al. Halofuglnone: an inhibitor of collagen type I synthesis. Biochim. Bioohys Acta 1993:1156:107 -12.
  • 2Spira G, Mawasi N, Paizi M, et cd. Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats. J Hepatol 2002: 37(3"J: 331 - 8.
  • 3Nagler A, Firman N, Feferman B, et al. Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med 1996; 154(4pt1): 1082- 6.
  • 4Halevy O, Nagler A, Levi-Schaffer V, et al. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients:effect of halofuginone. Biochem Pharmacol 1996; 52(7):1057 - 63.
  • 5Pines M, Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 1998; 30(4): 445 - 50.
  • 6Elkin M, Miao HQ, Nagler A, et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J 2000:14(15): 2477 -85.
  • 7Garish Z, Pinthus JH, Narak V, et al.Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 2002;51(2):73 - 83.
  • 8McGaha TL Phelps RG, Spiera H, et al. Halofuginone.an inhibitor of type-Icollagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002; 118(3):461-70.
  • 9McGaha TL, Kodera T, Spiera H, et cd. Halofuginone inhibition of COLI A2 promoter activity via a c-Jun-dependent mechanism. Arthritis Rheum 2002; 46(10):2748 - 61.

同被引文献121

引证文献13

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部